NCT03030248 2026-04-15
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Medical College of Wisconsin
Phase 2 Completed
Clinical Trials
110 trialsNCT02494258 2026-04-02
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Phase 2 Completed
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT05032820 2026-03-05
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
Phase 2 Completed
NCT05895994 2026-02-03
Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Completed
NCT03159702 2026-01-27
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Medical College of Wisconsin
Phase 2 Completed
NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed
NCT03578367 2025-11-10
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 2 Completed
NCT02158858 2025-10-08
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT03356171 2025-10-02
APACCHE
Centre Hospitalier Universitaire de la Réunion
Phase NA Completed
NCT01909934 2025-09-19
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
Phase 4 Completed
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT06904859 2025-04-01
The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia
Shenzhen University General Hospital
Phase EARLY_PHASE1 Completed
NCT05716113 2024-11-21
CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL
Zhejiang University
Phase EARLY_PHASE1 Completed
NCT05902845 2024-11-21
RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL
Anhui Provincial Hospital
Phase EARLY_PHASE1 Completed
NCT05907603 2024-11-21
Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
Xuzhou Medical University
Phase EARLY_PHASE1 Completed
NCT01183949 2024-08-02
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01716806 2024-06-11
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen Inc.
Phase 2 Completed
NCT02728102 2024-05-07
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT00457782 2024-04-25
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT04474678 2024-01-09
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
Medical University of Vienna
Phase NA Completed
NCT02661035 2023-09-21
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT03886909 2023-07-11
IMPROVE-BMT
Milton S. Hershey Medical Center
Phase NA Completed
NCT02124746 2023-06-18
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Phase 2 Completed
NCT02440464 2023-01-04
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT01423851 2022-03-09
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
NS Pharma, Inc.
Phase 1/2 Completed
NCT03111992 2022-02-09
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Novartis
Phase 1 Completed
NCT04039100 2022-02-08
Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease
Rigshospitalet, Denmark
Phase NA Completed
NCT01109004 2021-12-09
BMT CTN 0702
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT01777152 2021-11-30
ECHELON-2
Seagen Inc.
Phase 3 Completed
NCT02660281 2021-11-03
HaploOnly
University of Rochester
Phase 1 Completed
NCT03778606 2021-10-13
Oligosaccharide for Cdiff(+) Heme-onc Patients
Medical College of Wisconsin
Phase NA Completed
NCT00350181 2021-09-23
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Stanford University
Phase 2 Completed
NCT03895918 2021-09-16
Parenting Skills Intervention in Improving Medication Adherence in Pediatric Cancer Patients
Roswell Park Cancer Institute
Phase NA Completed
NCT02038036 2021-07-20
RESPONSE-2
Novartis
Phase 3 Completed
NCT00988013 2021-06-14
IM-TMI
University of Illinois at Chicago
Phase NA Completed
NCT02218047 2021-06-01
CONTI-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT01100502 2021-05-14
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Seagen Inc.
Phase 3 Completed
NCT00773747 2021-04-30
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01844765 2021-04-22
DIALOG
Novartis
Phase 2 Completed
NCT01990534 2021-04-09
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Takeda
Phase 4 Completed
NCT01670097 2021-02-17
Dexamethasone Dyspnea Study
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02678910 2020-12-09
Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis/Treatment
University of Kentucky
Phase NA Completed
NCT03176849 2020-11-17
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Phoenix Children's Hospital
Phase 4 Completed
NCT01369498 2020-07-01
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Gilead Sciences
Phase 2 Completed
NCT02322320 2020-05-11
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed